In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Atrial Fibrillation, SentreHEART Lassos An Advantage

Executive Summary

SentreHEART is operating in one of the most promising device spaces in stroke: percutaneous left atrial appendage closure. Unlike early movers, SentreHEART doesn’t leave an implant behind in the heart, and its LARIAT procedure might have unique benefits in addressing not only the stroke risk that comes with atrial fibrillation, but also AF itself.

Advertisement

Related Content

Cardiology Societies Urge Registry For Left-Atrial Appendage Closure Devices
Vascular Interventional Devices: New Avenues For Growth
Advisory Panel Endorses Boston Scientific’s Watchman Left Atrial Appendage Closure Device
LAA Closure Devices: Reaching Critical Mass?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel